poisar

Stocks · News reference

Tempest Therapeutics Exercises Option to License Senlang's CD7-Targeted Lentiviral In Vivo CAR-T Platform

Fiscal.ai

Tempest Therapeutics has exercised its option to obtain an exclusive license for Hebei Senlang Biotechnology's CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates for global development outside of China.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncNa

    Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update

    Tempest Therapeutics (TPST) announced it has exercised an option to obtain exclusive global rights (excluding China) to Senlang's CD7-targeted lentiviral vector platform and in vivo CAR-T candidates. The company's lead candidate TPST-4903, a BCMA/GPRC5D dual-targeting in vivo CAR-T, is in Phase 1 trials for relapsed/refractory multiple myeloma with encouraging preliminary results expected to be presented at an upcoming conference. Tempest also secured $50 million in equity line of credit access and $2.5 million in private placement funding, while strengthening its board with two new independent directors.